antithrombin

(redirected from ATryn)
Also found in: Dictionary, Medical.

antithrombin

[‚an·tē′thräm·bən]
(biochemistry)
A substance in blood plasma that inactivates thrombin.
Mentioned in ?
References in periodicals archive ?
ATryn was the world's first drug made in the milk of genetically altered animals.
ATryn is a therapeutic protein derived from the milk of genetically engineered goats.
GTC has granted OVATION the right to market ATryn in the U.S.
"The approval of ATryn marks a significant milestone in the development of this innovative recombinant technology and delivers a new therapeutic option to benefit hereditary antithrombin deficient patients who are undergoing surgery or childbirth procedures," said Geoffrey F.
In August 2006, ATryn, GTC's recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures.
The stakeholders of this report include companies and intermediaries engaged in the manufacture, commercialization, providing services of antithrombin products such as Antithrombin III, ATryn, and Antithrombin Gama and others as well as new entrants planning to enter this market.
The plan represents the first potential product expansion at rEVO, previously known as GTC Biotherapeutics, since it launched a clot-busting drug called ATryn in 2009.
commercialization rights to ATryn, a drug intended to prevent blood clots, from Lundbeck Inc., a wholly owned subsidiary of H.
GTC Biotherapeutics Inc.'s (Framingham MA) experimental anticlotting therapy, called Atryn, is made using a human protein gathered from female goats bred to produce it in their milk.
Yet bringing ATryn, an agent to regulate clotting in people with an inherited deficiency in the blood protein Antithrombin III, to market came with a cost.
It was recognized this quarter in connection with the signing of a definitive agreement with Lundbeck in July, whereby GTC Biotherapeutics regained commercialization rights to ATryn in the U.S.
Its clot-regulating drug, ATryn, was the first approved drug produced with an active molecule made in transgenic animals.